Literature DB >> 22613715

γ-Aminobutyric acid type B (GABAB) receptor expression is needed for inhibition of N-type (Cav2.2) calcium channels by analgesic α-conotoxins.

Hartmut Cuny1, Andrew de Faoite, Thuan G Huynh, Takahiro Yasuda, Géza Berecki, David J Adams.   

Abstract

α-Conotoxins Vc1.1 and RgIA are small peptides isolated from the venom of marine cone snails. They have effective anti-nociceptive actions in rat models of neuropathic pain. Pharmacological studies in rodent dorsal root ganglion (DRG) show their analgesic effect is mediated by inhibition of N-type (Ca(v)2.2) calcium channels via a pathway involving γ-aminobutyric acid type B (GABA(B)) receptor. However, there is no direct demonstration that functional GABA(B) receptors are needed for inhibition of the Ca(v)2.2 channel by analgesic α-conotoxins. This study examined the effect of the GABA(B) agonist baclofen and α-conotoxins Vc1.1 and RgIA on calcium channel currents after transient knockdown of the GABA(B) receptor using RNA interference. Isolated rat DRG neurons were transfected with small interfering RNAs (siRNA) targeting GABA(B) subunits R1 and R2. Efficient knockdown of GABA(B) receptor expression at mRNA and protein levels was confirmed by quantitative real time PCR (qRT-PCR) and immunocytochemical analysis, respectively. Whole-cell patch clamp recordings conducted 2-4 days after transfection showed that inhibition of N-type calcium channels in response to baclofen, Vc1.1 and RgIA was significantly reduced in GABA(B) receptor knockdown DRG neurons. In contrast, neurons transfected with a scrambled nontargeting siRNA were indistinguishable from untransfected neurons. In the HEK 293 cell heterologous expression system, Vc1.1 and RgIA inhibition of Ca(v)2.2 channels needed functional expression of both human GABA(B) receptor subunits. Together, these results confirm that GABA(B) receptors must be activated for the modulation of N-type (Ca(v)2.2) calcium channels by analgesic α-conotoxins Vc1.1 and RgIA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613715      PMCID: PMC3390670          DOI: 10.1074/jbc.M112.342998

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Analgesic α-conotoxins Vc1.1 and RgIA inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice.

Authors:  Brid Callaghan; David J Adams
Journal:  Channels (Austin)       Date:  2010-01-08       Impact factor: 2.581

2.  A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain.

Authors:  Harry Klimis; D J Adams; B Callaghan; S Nevin; P F Alewood; C W Vaughan; C A Mozar; M J Christie
Journal:  Pain       Date:  2011-02       Impact factor: 6.961

Review 3.  Targeting the alpha9alpha10 nicotinic acetylcholine receptor to treat severe pain.

Authors:  Michelle Vincler; J Michael McIntosh
Journal:  Expert Opin Ther Targets       Date:  2007-07       Impact factor: 6.902

4.  The three-dimensional structure of the analgesic alpha-conotoxin, RgIA.

Authors:  Richard J Clark; Norelle L Daly; Reena Halai; Simon T Nevin; David J Adams; David J Craik
Journal:  FEBS Lett       Date:  2008-01-31       Impact factor: 4.124

5.  Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.

Authors:  Brid Callaghan; Alison Haythornthwaite; Géza Berecki; Richard J Clark; David J Craik; David J Adams
Journal:  J Neurosci       Date:  2008-10-22       Impact factor: 6.167

6.  A high-throughput assay for evaluating state dependence and subtype selectivity of Cav2 calcium channel inhibitors.

Authors:  Ge Dai; Rodolfo J Haedo; Vivien A Warren; Kevin S Ratliff; Randal M Bugianesi; Alison Rush; Mark E Williams; James Herrington; McHardy M Smith; Owen B McManus; Andrew M Swensen
Journal:  Assay Drug Dev Technol       Date:  2008-04       Impact factor: 1.738

Review 7.  Pharmacologic management of neuropathic pain: evidence-based recommendations.

Authors:  Robert H Dworkin; Alec B O'Connor; Miroslav Backonja; John T Farrar; Nanna B Finnerup; Troels S Jensen; Eija A Kalso; John D Loeser; Christine Miaskowski; Turo J Nurmikko; Russell K Portenoy; Andrew S C Rice; Brett R Stacey; Rolf-Detlef Treede; Dennis C Turk; Mark S Wallace
Journal:  Pain       Date:  2007-10-24       Impact factor: 6.961

8.  Opioid-related (ORL1) receptors are enriched in a subpopulation of sensory neurons and prolonged activation produces no functional loss of surface N-type calcium channels.

Authors:  Swetha S Murali; Ian A Napier; Beth K Rycroft; MacDonald J Christie
Journal:  J Physiol       Date:  2012-02-27       Impact factor: 5.182

9.  Ethanol and PTZ effects on siRNA-mediated GABAB1 receptor: down regulation of intracellular signaling pathway in prenatal rat cortical and hippocampal neurons.

Authors:  M I Naseer; H Y Lee; N Ullah; I Ullah; M S Park; S H Kim; M O Kim
Journal:  Synapse       Date:  2010-03       Impact factor: 2.562

Review 10.  Neuropathic pain: emerging treatments.

Authors:  A Dray
Journal:  Br J Anaesth       Date:  2008-05-28       Impact factor: 9.166

View more
  25 in total

1.  Identifying key amino acid residues that affect α-conotoxin AuIB inhibition of α3β4 nicotinic acetylcholine receptors.

Authors:  Anton A Grishin; Hartmut Cuny; Andrew Hung; Richard J Clark; Andreas Brust; Kalyana Akondi; Paul F Alewood; David J Craik; David J Adams
Journal:  J Biol Chem       Date:  2013-10-07       Impact factor: 5.157

2.  Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.

Authors:  Sulan Luo; Dongting Zhangsun; Peta J Harvey; Quentin Kaas; Yong Wu; Xiaopeng Zhu; Yuanyan Hu; Xiaodan Li; Victor I Tsetlin; Sean Christensen; Haylie K Romero; Melissa McIntyre; Cheryl Dowell; James C Baxter; Keith S Elmslie; David J Craik; J Michael McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

Review 3.  α9-containing nicotinic acetylcholine receptors and the modulation of pain.

Authors:  Arik J Hone; Denis Servent; J Michael McIntosh
Journal:  Br J Pharmacol       Date:  2017-07-30       Impact factor: 8.739

4.  A 'conovenomic' analysis of the milked venom from the mollusk-hunting cone snail Conus textile--the pharmacological importance of post-translational modifications.

Authors:  Zachary L Bergeron; Joycelyn B Chun; Margaret R Baker; David W Sandall; Steve Peigneur; Peter Y C Yu; Parashar Thapa; Jeffrey W Milisen; Jan Tytgat; Bruce G Livett; Jon-Paul Bingham
Journal:  Peptides       Date:  2013-09-18       Impact factor: 3.750

5.  Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.

Authors:  Haylie K Romero; Sean B Christensen; Lorenzo Di Cesare Mannelli; Joanna Gajewiak; Renuka Ramachandra; Keith S Elmslie; Douglas E Vetter; Carla Ghelardini; Shawn P Iadonato; Jose L Mercado; Baldomera M Olivera; J Michael McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

6.  αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype.

Authors:  Dongting Zhangsun; Xiaopeng Zhu; Quentin Kaas; Yong Wu; David J Craik; J Michael McIntosh; Sulan Luo
Journal:  Neuropharmacology       Date:  2017-04-14       Impact factor: 5.250

Review 7.  GABAB Receptors and Pain.

Authors:  Dietmar Benke
Journal:  Curr Top Behav Neurosci       Date:  2022

8.  Presence of multiple binding sites on α9α10 nAChR receptors alludes to stoichiometric-dependent action of the α-conotoxin, Vc1.1.

Authors:  Dinesh C Indurthi; Elena Pera; Hye-Lim Kim; Cindy Chu; Malcolm D McLeod; J Michael McIntosh; Nathan L Absalom; Mary Chebib
Journal:  Biochem Pharmacol       Date:  2014-02-15       Impact factor: 5.858

9.  Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.

Authors:  G Berecki; N L Daly; Y H Huang; S Vink; D J Craik; P F Alewood; D J Adams
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 10.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.

Authors:  Gerald W Zamponi; Joerg Striessnig; Alexandra Koschak; Annette C Dolphin
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.